Development of a drug delivery system for efficient alveolar delivery of a neutralizing monoclonal antibody to treat pulmonary intoxication to ricin

Journal of Controlled Release

Volumn 234, Issue , 2016, Pages 21-32

  Respaud, Renaud ^a,b   Marchand, Denis ^a,b,n   Pelat, Thibaut ^c,k   Tchou Wong, Kam Meng ^d   Roy, Chad J ^e,f   Parent, Christelle ^a,b   Cabrera, Maria ^a,b   Guillemain, Joël ^g   Mac Loughlin, Ronan ^h   Levacher, Eric ⁱ   Fontayne, Alexandre ^j   Douziech Eyrolles, Laurence ^l   Junqua Moullet, Alexandra ^m   Guilleminault, Laurent ^a,b   Thullier, Philippe ^c   Guillot Combe, Emmanuelle ^o   Vecellio, Laurent ^a,b,n   Heuzé Vourc'h, Nathalie ^a,b  

^a UNIVERSITÉ DE TOURS   (France)

^b Université Franaois Rabelais   (France)

^c INSTITUT DE RECHERCHE BIOMÉDICALE DES ARMÉES   (France)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

^g c/o UNESCO Amman Office   (France)

^h Aerogen Ltd   (Ireland)

ⁱ Groupe IMT   (France)

^j LFB Biotechnologies Research Department   (France)

^k BIOTEM   (France)

^l Université de Tours   (France)

^m CEA LE RIPAULT   (France)

ⁿ DTF Aerodrug   (France)

^o DGA   (France)

more..

Author keywords

Aerosol therapy; Bioweapon; Formulation; Mesh nebulizer; Monoclonal antibody; Ricin intoxication

Indexed keywords

AEROSOLS; BIOLOGICAL WEAPONS; DEPOSITION; MAMMALS; MESH GENERATION; MONOCLONAL ANTIBODIES;

BIOWEAPONS; DRUG DELIVERY SYSTEM; FORMULATION; MESH NEBULIZER; OPERATIONAL CONSTRAINTS; RICIN INTOXICATION; STABILIZING SOLUTIONS; THERAPEUTIC STRATEGY;

ANTIBODIES;

ANTIDOTE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 43RCA G1; NEUTRALIZING ANTIBODY; RICIN; RICIN A; RICIN ANTIBODY; UNCLASSIFIED DRUG; CHEMICAL WARFARE AGENT;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY AFFINITY; ANTIBODY COMBINING SITE; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; DRY POWDER; FEMALE; FREEZE DRYING; LUNG TOXICITY; MALE; MOUSE; NEBULIZATION; NEBULIZER; NONHUMAN; PARTICLE SIZE; POWER SUPPLY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN FUNCTION; THERAPEUTIC INDEX; ANIMAL; BAGG ALBINO MOUSE; CHEMICALLY INDUCED; DRUG EFFECTS; HUMAN; JURKAT CELL LINE; LUNG ALVEOLUS; LUNG INJURY; MACACA FASCICULARIS; PROCEDURES; TISSUE DISTRIBUTION;

AEROSOLS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; CHEMICAL WARFARE AGENTS; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; JURKAT CELLS; LUNG INJURY; MACACA FASCICULARIS; MALE; MICE, INBRED BALB C; NEBULIZERS AND VAPORIZERS; PULMONARY ALVEOLI; RICIN; TISSUE DISTRIBUTION;

EID: 84975245285     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2016.05.018     Document Type: Article

References (76)

1. [1] Romano, J.A., Lukey, B.J., Salem, H., Chemical Warfare Agents: Chemistry, Pharmacology, Toxicology, and Therapeutics. second ed., 2007, CRC Press.
2. [2] Balali-Mood, M., Moshiri, M., Etemad, L., Medical aspects of bio-terrorism. Toxicon Off. J. Int. Soc. Toxinology. 69 (2013), 131–142, 10.1016/j.toxicon.2013.01.005.
3. [3] Lord, J.M., Roberts, L.M., Robertus, J.D., Ricin: structure, mode of action, and some current applications. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 8 (1994), 201–208.
4. [4] Endo, Y., Tsurugi, K., Ebert, R.F., The mechanism of action of barley toxin: a type 1 ribosome-inactivating protein with RNA N-glycosidase activity. Biochim. Biophys. Acta 954 (1988), 224–226.
5. [5] Endo, Y., Tsurugi, K., RNA N-glycosidase activity of ricin A-chain. Mechanism of action of the toxic lectin ricin on eukaryotic ribosomes. J. Biol. Chem. 262 (1987), 8128–8130.
6. [6] Audi, J., Belson, M., Patel, M., Schier, J., Osterloh, J., Ricin poisoning: a comprehensive review. J. Am. Med. Assoc. 294 (2005), 2342–2351, 10.1001/jama.294.18.2342.
7. [7] Roy, C.J., Hale, M., Hartings, J.M., Pitt, L., Duniho, S., Impact of inhalation exposure modality and particle size on the respiratory deposition of ricin in BALB/c mice. Inhal. Toxicol. 15 (2003), 619–638, 10.1080/08958370390205092.
8. [8] Reisler, R.B., Smith, L.A., The need for continued development of ricin countermeasures. Adv. Prev. Med., 2012, 2012, 149737, 10.1155/2012/149737.
9. [9] Pincus, S.H., Bhaskaran, M., Brey, R.N., Didier, P.J., Doyle-Meyers, L.A., Roy, C.J., Clinical and pathological findings associated with aerosol exposure of macaques to ricin toxin. Toxins 7 (2015), 2121–2133, 10.3390/toxins7062121.
10. [10] Marconescu, P.S., Smallshaw, J.E., Pop, L.M., Ruback, S.L., Vitetta, E.S., Intradermal administration of RiVax protects mice from mucosal and systemic ricin intoxication. Vaccine 28 (2010), 5315–5322, 10.1016/j.vaccine.2010.05.045.
11. [11] Froude, J.W., Stiles, B., Pelat, T., Thullier, P., Antibodies for biodefense. MAbs 3 (2011), 517–527, 10.4161/mabs.3.6.17621.
12. [12] Roy, C.J., Brey, R.N., Mantis, N.J., Mapes, K., Pop, I.V., Pop, L.M., et al. Thermostable ricin vaccine protects rhesus macaques against aerosolized ricin: epitope-specific neutralizing antibodies correlate with protection. Proc. Natl. Acad. Sci. U. S. A. 112 (2015), 3782–3787, 10.1073/pnas.1502585112.
13. [13] Vitetta, E.S., Smallshaw, J.E., Schindler, J., Pilot phase IB clinical trial of an alhydrogel-adsorbed recombinant ricin vaccine. Clin. Vaccine Immunol. 19 (2012), 1697–1699, 10.1128/CVI.00381-12.
14. [14] Reichert, J.M., Antibodies to watch in 2016. MAbs, 2015, 1–8, 10.1080/19420862.2015.1125583.
15. [15] Reichert, J.M., Dhimolea, E., The future of antibodies as cancer drugs. Drug Discov. Today 17 (2012), 954–963, 10.1016/j.drudis.2012.04.006.
16. [16] Reichert, J.M., Marketed therapeutic antibodies compendium. MAbs 4 (2012), 413–415, 10.4161/mabs.19931.
17. [17] O'Hara, J.M., Yermakova, A., Mantis, N.J., Immunity to ricin: fundamental insights into toxin-antibody interactions. Curr. Top. Microbiol. Immunol. 357 (2012), 209–241, 10.1007/82_2011_193.
18. [18] Wu, F., Fan, S., Martiniuk, F., Pincus, S., Müller, S., Kohler, H., et al. Protective effects of anti-ricin A-chain antibodies delivered intracellularly against ricin-induced cytotoxicity. World J. Biol. Chem. 1 (2010), 188–195, 10.4331/wjbc.v1.i5.188.
19. [19] Pincus, S.H., Smallshaw, J.E., Song, K., Berry, J., Vitetta, E.S., Passive and active vaccination strategies to prevent ricin poisoning. Toxins 3 (2011), 1163–1184, 10.3390/toxins3091163.
20. [20] Pratt, T.S., Pincus, S.H., Hale, M.L., Moreira, A.L., Roy, C.J., Tchou-Wong, K.-M., Oropharyngeal aspiration of ricin as a lung challenge model for evaluation of the therapeutic index of antibodies against ricin A-chain for post-exposure treatment. Exp. Lung Res. 33 (2007), 459–481, 10.1080/01902140701731805.
21. [21] Diakite, M.L.Y., Rollin, J., Jary, D., Berthier, J., Mourton-Gilles, C., Sauvaire, D., et al. Point-of-care diagnostics for ricin exposure. Lab Chip 15 (2015), 2308–2317, 10.1039/c5lc00178a.
22. [22] Guglielmo-Viret, V., Splettstoesser, W., Thullier, P., An immunochromatographic test for the diagnosis of ricin inhalational poisoning. Clin. Toxicol. (Phila.) 45 (2007), 505–511, 10.1080/15563650701354226.
23. [23] Hart, T.K., Cook, R.M., Zia-Amirhosseini, P., Minthorn, E., Sellers, T.S., Maleeff, B.E., et al. Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys. J. Allergy Clin. Immunol. 108 (2001), 250–257, 10.1067/mai.2001.116576.
24. [24] Dall'Acqua, W.F., Kiener, P.A., Wu, H., Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J. Biol. Chem. 281 (2006), 23514–23524, 10.1074/jbc.M604292200.
25. [25] Maillet, A., Guilleminault, L., Lemarié, E., Lerondel, S., Azzopardi, N., Montharu, J., et al. The airways, a novel route for delivering monoclonal antibodies to treat lung tumors. Pharm. Res. 28 (2011), 2147–2156, 10.1007/s11095-011-0442-5.
26. [26] Hervé, V., Rabbe, N., Guilleminault, L., Paul, F., Schlick, L., Azzopardi, N., et al. VEGF neutralizing aerosol therapy in primary pulmonary adenocarcinoma with K-ras activating-mutations. MAbs 6 (2014), 1638–1648, 10.4161/mabs.34454.
27. [27] Guilleminault, L., Azzopardi, N., Arnoult, C., Sobilo, J., Herve, V., Montharu, J., et al. Fate of inhaled monoclonal antibodies after the deposition of aerosolized particles in the respiratory system. J. Control. Release 196 (2014), 344–354, 10.1016/j.jconrel.2014.10.003.
28. [28] Respaud, R., Vecellio, L., Diot, P., Heuzé-Vourc'h, N., Nebulization as a delivery method for mAbs in respiratory diseases. Expert Opin. Drug Deliv. 12 (2015), 1027–1039, 10.1517/17425247.2015.999039.
29. [29] Koussoroplis, S.J., Paulissen, G., Tyteca, D., Goldansaz, H., Todoroff, J., Barilly, C., et al. PEGylation of antibody fragments greatly increases their local residence time following delivery to the respiratory tract. J. Control. Release Off. J. Control. Release Soc. 187 (2014), 91–100, 10.1016/j.jconrel.2014.05.021.
30. [30] Maillet, A., Congy-Jolivet, N., Le Guellec, S., Vecellio, L., Hamard, S., Courty, Y., et al. Aerodynamical, immunological and pharmacological properties of the anticancer antibody cetuximab following nebulization. Pharm. Res. 25 (2008), 1318–1326, 10.1007/s11095-007-9481-3.
31. [31] Respaud, R., Marchand, D., Parent, C., Pelat, T., Thullier, P., Tournamille, J.-F., et al. Effect of formulation on the stability and aerosol performance of a nebulized antibody. MAbs, 6, 2014.
32. [32] Pelat, T., Hust, M., Hale, M., Lefranc, M.-P., Dübel, S., Thullier, P., Isolation of a human-like antibody fragment (scFv) that neutralizes ricin biological activity. BMC Biotechnol., 9, 2009, 60, 10.1186/1472-6750-9-60.
33. [33] US20130184440A1—Google Patents, https://patents.google.com/patent/US20130184440A1/en (accessed November 9, 2015). (n.d.).
34. [34] WO2009053637A3—Google Patents, https://patents.google.com/patent/WO2009053637A3/fr (accessed November 9, 2015). (n.d.).
35. [35] Pelat, T., Bedouelle, H., Rees, A.R., Crennell, S.J., Lefranc, M.-P., Thullier, P., Germline humanization of a non-human primate antibody that neutralizes the anthrax toxin, by in vitro and in silico engineering. J. Mol. Biol. 384 (2008), 1400–1407, 10.1016/j.jmb.2008.10.033.
36. [36] Pelat, T., Thullier, P., Non-human primate immune libraries combined with germline humanization: an (almost) new, and powerful approach for the isolation of therapeutic antibodies. MAbs 1 (2009), 377–381.
37. [37] Rousseau, J.-M., Besse Bardot, I., Franck, L., Libert, N., Lallement, G., Clair, P., [Interest of Ineurope syringe for nerve agent intoxication]. Ann. Fr. Anesth. Rèanim. 28 (2009), 482–488, 10.1016/j.annfar.2009.02.039.
38. [38] Schuck, P., Minton, A.P., Kinetic analysis of biosensor data: elementary tests for self-consistency. Trends Biochem. Sci. 21 (1996), 458–460.
39. [39] Pratt, T.S., Pincus, S.H., Hale, M.L., Moreira, A.L., Roy, C.J., Tchou-Wong, K.-M., Oropharyngeal aspiration of ricin as a lung challenge model for evaluation of the therapeutic index of antibodies against ricin A-chain for post-exposure treatment. Exp. Lung Res. 33 (2007), 459–481, 10.1080/01902140701731805.
40. [40] A.P. Minton, Recent applications of light scattering measurement in the biological and biopharmaceutical sciences, Anal. Biochem. doi: http://dx.doi.org/10.1016/j.ab.2016.02.007. (n.d.).
41. [41] Lelong, N., Junqua-Moullet, A., Diot, P., Vecellio, L., Comparison of laser diffraction measurements by Mastersizer X and Spraytec to characterize droplet size distribution of medical liquid aerosols. J. Aerosol Med. Pulm. Drug Deliv. 27 (2014), 94–102, 10.1089/jamp.2012.1030.
42. [42] Vecellio None, L., Grimbert, D., Bordenave, J., Benoit, G., Furet, Y., Fauroux, B., et al. Residual gravimetric method to measure nebulizer output. J. Aerosol Med. Off. J. Int. Soc. Aerosols Med. 17 (2004), 63–71, 10.1089/089426804322994479.
43. [43] European Committee for Standardization. EN13544-1:2007. Respiratory therapy equipment, part 1: Nebulizing systems and thei components. (n.d.).
44. [44] Gatnash, A.A., Chandler, S.T., Connolly, C.K., A new method for measuring aerosol nebulizer output using radioactive tracers. Eur. Respir. J. 12 (1998), 467–471.
45. [45] Sangwan, S., Condos, R., Smaldone, G.C., Lung deposition and respirable mass during wet nebulization. J. Aerosol Med. Off. J. Int. Soc. Aerosols Med. 16 (2003), 379–386, 10.1089/089426803772455631.
46. [46] Smaldone, G.C., Drug delivery via aerosol systems: concept of “aerosol inhaled,”. J. Aerosol Med. Off. J. Int. Soc. Aerosols Med. 4 (1991), 229–235.
47. [47] Scheuch, G., Bennett, W., Borgström, L., Clark, A., Dalby, R., Dolovich, M., et al. Deposition, imaging, and clearance: what remains to be done?. J. Aerosol Med. Pulm. Drug Deliv. 23:Suppl. 2 (2010), S39–S57, 10.1089/jamp.2010.0839.
48. [48] Ribeiro, A.L.T., Shimada, A.L.B., Hebeda, C.B., de Oliveira, T.F., de Melo Loureiro, A.P., Filho, W.D.R.P., et al. In vivo hydroquinone exposure alters circulating neutrophil activities and impairs LPS-induced lung inflammation in mice. Toxicology 288 (2011), 1–7, 10.1016/j.tox.2011.05.009.
49. [49] Thullier, P., Huish, O., Pelat, T., Martin, A.C.R., The humanness of macaque antibody sequences. J. Mol. Biol. 396 (2010), 1439–1450, 10.1016/j.jmb.2009.12.041.
50. [50] Abhinandan, K.R., Martin, A.C.R., Analyzing the “degree of humanness” of antibody sequences. J. Mol. Biol. 369 (2007), 852–862, 10.1016/j.jmb.2007.02.100.
51. [51] Ward, E.S., Ober, R.J., Chapter 4: multitasking by exploitation of intracellular transport functions the many faces of FcRn. Adv. Immunol. 103 (2009), 77–115, 10.1016/S0065-2776(09)03004-1.
52. [52] Roopenian, D.C., Akilesh, S., FcRn: the neonatal fc receptor comes of age. Nat. Rev. Immunol. 7 (2007), 715–725, 10.1038/nri2155.
53. [53] Nissim, A., Chernajovsky, Y., Historical development of monoclonal antibody therapeutics. Handb. Exp. Pharmacol., 3–18, 2008, 10.1007/978-3-540-73259-4_1.
54. [54] Griffiths, G.D., Phillips, G.J., Holley, J., Inhalation toxicology of ricin preparations: animal models, prophylactic and therapeutic approaches to protection. Inhal. Toxicol. 19 (2007), 873–887, 10.1080/08958370701432124.
55. [55] R. Respaud, L. Vecellio, P. Diot, N. heuze-Vourc'h, Nebulization as a delivery method for monoclonal antibodies in respiratory diseases, Expert Opin. Drug Deliv. doi: http://dx.doi.org/10.1517/17425247.2015.999039. (n.d.).
56. [56] Roy, C.J., Reed, D.S., Hutt, J.A., Aerobiology and inhalation exposure to biological select agents and toxins. Vet. Pathol. 47 (2010), 779–789, 10.1177/0300985810378650.
57. [57] Doebler, J.A., Wiltshire, N.D., Mayer, T.W., Estep, J.E., Moeller, R.B., Traub, R.K., et al. The distribution of [125I]ricin in mice following aerosol inhalation exposure. Toxicology 98 (1995), 137–149.
58. [58] Bradberry, S.M., Dickers, K.J., Rice, P., Griffiths, G.D., Vale, J.A., Ricin poisoning. Toxicol. Rev. 22 (2003), 65–70.
59. [59] Lindler, L.E., Lebeda, F.J., Korch, G., Biological Weapons Defense: Infectious Disease and Counterbioterrorism. 2007, Springer Science & Business Media.
60. [60] Wang, W., Singh, S., Zeng, D.L., King, K., Nema, S., Antibody structure, instability, and formulation. J. Pharm. Sci. 96 (2007), 1–26, 10.1002/jps.20727.
61. [61] Angkawinitwong, U., Sharma, G., Khaw, P.T., Brocchini, S., Williams, G.R., Solid-state protein formulations. Ther. Deliv. 6 (2015), 59–82, 10.4155/tde.14.98.
62. [62] Depreter, F., Pilcer, G., Amighi, K., Inhaled proteins: challenges and perspectives. Int. J. Pharm. 447 (2013), 251–280, 10.1016/j.ijpharm.2013.02.031.
63. [63] Shoyele, S.A., Slowey, A., Prospects of formulating proteins/peptides as aerosols for pulmonary drug delivery. Int. J. Pharm. 314 (2006), 1–8, 10.1016/j.ijpharm.2006.02.014.
64. [64] Pilcer, G., Amighi, K., Formulation strategy and use of excipients in pulmonary drug delivery. Int. J. Pharm. 392 (2010), 1–19, 10.1016/j.ijpharm.2010.03.017.
65. [65] European Pharmacopeia 8th Edition (8.5), Preparations for inhalation - Inhalanda. 01/2012:0671. Available from:http://online6edqmeu/ep805/[Website], 2015, 862–868 (n.d.).
66. [66] Barth, A., Infrared spectroscopy of proteins. Biochim. Biophys. Acta BBA - Bioenerg. 1767 (2007), 1073–1101, 10.1016/j.bbabio.2007.06.004.
67. [67] Zhang, G., David, A., Wiedmann, T.S., Performance of the vibrating membrane aerosol generation device: Aeroneb Micropump nebulizer. J. Aerosol Med. Off. J. Int. Soc. Aerosols Med. 20 (2007), 408–416, 10.1089/jam.2007.0622.
68. [68] European Pharmacopoeia 8th Edition (8.5), Chapter 2.09.44: preparation for nebulization-characterization. Available from: http://online6edqmeu/ep805/[Website], 2015 (n.d.).
69. [69] Ghazanfari, T., Elhissi, A.M.A., Ding, Z., Taylor, K.M.G., The influence of fluid physicochemical properties on vibrating-mesh nebulization. Int. J. Pharm. 339 (2007), 103–111, 10.1016/j.ijpharm.2007.02.035.
70. [70] Rao, N., Kadrichu, N., Ament, B., Application of a droplet evaporation model to aerodynamic size measurement of drug aerosols generated by a vibrating mesh nebulizer. J. Aerosol Med. Pulm. Drug Deliv. 23 (2010), 295–302, 10.1089/jamp.2009.0805.
71. [71] Phalen, R.F., Oldham, M.J., Wolff, R.K., The relevance of animal models for aerosol studies. J. Aerosol Med. Pulm. Drug Deliv. 21 (2008), 113–124, 10.1089/jamp.2007.0673.
72. [72] Chapman, K., Pullen, N., Coney, L., Dempster, M., Andrews, L., Bajramovic, J., et al. Preclinical development of monoclonal antibodies: considerations for the use of non-human primates. MAbs 1 (2009), 505–516.
73. [73] Pitance, L., Vecellio, L., Leal, T., Reychler, G., Reychler, H., Liistro, G., Delivery efficacy of a vibrating mesh nebulizer and a jet nebulizer under different configurations. J. Aerosol Med. Pulm. Drug Deliv. 23 (2010), 389–396, 10.1089/jamp.2010.0816.
74. [74] Albuquerque-Silva, I., Vecellio, L., Durand, M., Avet, J., Le Pennec, D., de Monte, M., et al. Particle deposition in a child respiratory tract model: in vivo regional deposition of fine and ultrafine aerosols in baboons. PLoS ONE, 9, 2014, e95456, 10.1371/journal.pone.0095456.
75. [75] Marchand, S., Bouchene, S., de Monte, M., Guilleminault, L., Montharu, J., Cabrera, M., et al. Pharmacokinetics of Colistin Methansulphonate (CMS) and Colistin after CMS nebulisation in Baboon Monkeys. Pharm. Res. 32 (2015), 3403–3414, 10.1007/s11095-015-1716-0.
76. [76] Chua, H.L., Collis, G.G., Newbury, A.M., Chan, K., Bower, G.D., Sly, P.D., et al. The influence of age on aerosol deposition in children with cystic fibrosis. Eur. Respir. J. 7 (1994), 2185–2191.